A Snapshot Of Bristol Myers Squibb’s Phase 3 Drug Pipeline

by Trefis Team
+7.21%
Upside
52.12
Market
55.88
Trefis
BMY
Bristol-Myers Squibb
Rate   |   votes   |   Share

We estimate that Bristol-Myers Squibb’s (NYSE:BMY) phase 3 drug pipeline (not counting the enhancement of currently marketed products) could be worth around $2 billion. We have created an interactive dashboard on BMY’s phase 3 pipeline, which includes breakup of new compound, estimated peak sales, probability of approval, and the resulting probability adjusted revenues. Note that you can adjust the probability, and estimated peak sales of the new compounds.

Prostvac Is The Key Drug In Phase 3 Pipeline

  • We estimate 50% probability of a drug being approved by the regulators.
  • Prostvac peak sales are estimated to be $1.3 billion.
  • The drug is expected to be approved in 2018.
  • Our current forecast for the drug sales to achieve full potential is 7 years.

BMY’s Overall Pipeline

  • IDO Inhibitor(1) is also currently under phase 3 trial.
  • While BMY’s phase 3 pipeline of new drugs looks small, the company is focused on expanding Opdivo’s therapeutic uses, and is testing the drug with different combinations, such as Yervoy among others.
  • Opdivo is currently being tested alone and in different combinations for the treatment of different tumor types, including lung, head & neck, liver, kidney, bladder and gastric. 
  • Overall, the company has 41 new compounds in different stages of trials.

Our price estimate of $60 for Bristol Myers Squibb implies a discount of over 10% to the market.

What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Research

Like our charts? Explore example interactive dashboards and create your own

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!